Latest Breaking News On - Jesse shefferman - Page 4 : comparemela.com

Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic . Protara TherapeuticsApril 23, 2021 GMT NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which there is no U.S. Food and Drug Administration (FDA)-approved treatment. Based on feedback from the FDA, the Company intends to complete confirmatory, large-scale, GMP manufacturing comparability in the second half of 2021 and subsequently initiate a clinical study in pediatric LM patients pending alignment with FDA on study design.

Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations

Provided by GlobeNewswire Apr 23, 2021 11:00 AM UTC NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which there is no U.S. Food and Drug Administration (FDA)-approved treatment. Based on feedback from the FDA, the Company intends to complete confirmatory, large-scale, GMP manufacturing comparability in the second half of 2021 and subsequently initiate a clinical study in pediatric LM patients pending alignment with FDA on study design.

Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer

Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer

Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors

Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors February 02, 2021 08:00 ET | Source: Protara Therapeutics Protara Therapeutics New York, New York, UNITED STATES NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Cynthia Smith to its Board of Directors. Ms. Smith brings to Protara over 20 years of diverse leadership experience within the healthcare industry, most recently serving as Chief Commercial Officer at ZS Pharma. “It is with great excitement that we welcome Cynthia to our Board of Directors,” said Jesse Shefferman